Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 33,170 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Knee Osteoarthritis
Interventions: Micronized dHACM, Saline; Biological · Drug
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 17
States / cities: Birmingham, Alabama • Tempe, Arizona • La Mesa, California + 14 more

Conditions: Episodic Migraine
Interventions: Botulinum toxin type A, Placebo; Biological · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 66
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 58 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes, Obesity
Interventions: Cagrilintide, Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 25
States / cities: Concord, California • Fresno, California • Palm Springs, California + 22 more

Conditions: Heterozygous Familial Hypercholesterolemia (HeFH)
Interventions: Enlicitide Decanoate, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 8
States / cities: Wilmington, Delaware • Washington D.C., District of Columbia • Boca Raton, Florida + 5 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Mitiperstat (AZD4831), Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 19
States / cities: Newport Beach, California • Clearwater, Florida • DeLand, Florida + 16 more

Conditions: Pancreatic Neoplasm
Interventions: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo, Gemcitabine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-06291874, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Anaheim, California • Chula Vista, California • South Miami, Florida

Conditions: Osteoarthritis
Interventions: Oxycodone, Placebo, PF-000592379; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 21
States / cities: Mobile, Alabama • Tucson, Arizona • Carmichael, California + 17 more

Conditions: Hepatitis C Virus, HCV Infection, Chronic HCV, Hepatitis C
Interventions: Naringenin; Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: KBP-7072, Placebo; Drug
Lead sponsor: KBP Biosciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Sitaxsentan, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 32
States / cities: Fountain Valley, California • Mather, California • Sacramento, California + 28 more

Conditions: Diabetes Mellitus, Ischemic Heart Disease
Interventions: 100 million Allogeneic Mesenchymal Human Stem Cells, Placebo; Drug · Other
Lead sponsor: Joshua M Hare; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Psoriasis Vulgaris
Interventions: PTH (1-34) Gel / Placebo Gel; Drug
Lead sponsor: Manhattan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: San Diego, California • Ormond Beach, Florida • Fridley, Minnesota + 1 more

Conditions: Chronic Kidney Disease
Interventions: Paricalcitol, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Dengue
Interventions: ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC), Placebo; Drug · Other
Lead sponsor: Island Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: East Syracuse, New York

Conditions: Osteoporosis
Interventions: Bazedoxifene Acetate, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 7,609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 205
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 141 more

Conditions: Chronic Pain, Nociceptive Pain, Pain
Interventions: CNTX-6016, Other: Placebo; Drug · Other
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Major Depressive Disorder (MDD)
Interventions: GeneSight Psychotropic; Genetic
Lead sponsor: Assurex Health Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 61
States / cities: Birmingham, Alabama • Bellflower, California • Chino, California + 52 more

Conditions: Allergic Conjunctivitis
Interventions: Prednisolone Sodium Phosphate Ophthalmic Solution 1%, Tears Naturale II Ophthalmic Solution; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Mild Cognitive Impairment
Interventions: Aricept (donepezil hydrochloride), placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 45 Years to 90 Years
Enrollment: 145 participants
Timeline: 2006 – 2007
U.S. locations: 49
States / cities: Alabaster, Alabama • Peoria, Arizona • Sun City, Arizona + 43 more

Conditions: Cocaine Dependence
Interventions: levodopa/carbidopa, Ropinirole 2 mg/d, Placebo, Ropinirole 4 mg/d; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 55 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Irregular Sleep-Wake Rhythm Disorder
Interventions: Lemborexant 2.5 mg, Lemborexant 5 mg, Lemborexant 10 mg, Lemborexant 15 mg, Lemborexant-matched placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 60 Years to 90 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 37
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Costa Mesa, California + 30 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: ND-L02-s0201 (Low Dose), ND-L02-s0201 (High Dose), Other: Placebo; Drug · Other
Lead sponsor: Nitto Denko Corporation; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 21
States / cities: Tucson, Arizona • Los Angeles, California • Northridge, California + 18 more

Conditions: Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Interventions: Placebo, Enicepatide; Drug
Lead sponsor: Carmot Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 52
States / cities: Birmingham, Alabama • Guntersville, Alabama • Yuma, Arizona + 45 more

Search by objective public record fields.

Micronized dHACM vs. Saline in the Treatment of Osteoarthritis of the Knee

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer

PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients

A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee

A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection

A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis

Metabolic Effects of Paricalcitol

Study to Examine the Effects of Oral Fenretinide

Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women

A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects

Genomics Used to Improve DEpression Decisions

Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

Cognitive Remediation for Cocaine Dependence

Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia

JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus